Every material Form 8-K ADC Therapeutics SA has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ADC Therapeutics reported third quarter 2026 results, with net product revenue of $21.0 million, up from $15.8 million a year earlier, and a net loss of $25.3 million, or $0.16 per share, versus $41.0 million, or $0.30 per share, in the prior-year quarter. Cash and cash equivalents were $189.2 million at September 30, 2026, down from $261.3 million at December 31, 2025, and the company said its October 2026 financing restructuring extends its expected cash runway into 2029.
Q3 2026 net product revenue was $21.0 million, compared with $15.8 million in Q3 2025; license revenue and royalties were $0.7 million in both periods.
Q3 2026 net loss was $25.3 million ($0.16 per share), compared with $41.0 million ($0.30 per share) a year earlier; adjusted net loss was $8.8 million.
Cash and cash equivalents were $189.2 million at September 30, 2026, versus $261.3 million at December 31, 2025.
October 2026 restructuring included an $86.6 million PIPE financing, elimination of a $150 million change-of-control payment, and a reduction of the senior secured loan principal by $68.5 million to $50 million.
ADC Therapeutics released preliminary third-quarter 2026 figures and new ZYNLONTA trial data to be presented at the December 2026 ASH meeting. The company expects net product revenue of $21 million for the quarter ended September 30, 2026, and reported cash and cash equivalents of $189.2 million as of that date, but the figures are unaudited and not finalized. The filing also notes that the FDA raised serious concerns about the LOTIS-5 trial results at a recent pre-sBLA meeting.
Expected net product revenue from ZYNLONTA of $21 million for the quarter ended September 30, 2026; the company has not finalized these results.
Cash and cash equivalents of $189.2 million as of September 30, 2026; the company cites an expected cash runway into 2029.
LOTIS-7 Phase 1b study showed an 88.7% overall response rate and 75.3% complete response rate among 97 efficacy-evaluable patients.
The filing cites FDA concerns about LOTIS-5 trial results raised at a recent pre-sBLA submission meeting.
ADC Therapeutics agreed on October 7, 2026 to sell equity in an $86.6 million private placement, with closing expected October 22, 2026. The company also amended its term loan, cutting principal to $50.0 million, and amended its HealthCare Royalty agreement, removing a $150 million change-of-control payment. The filing gives preliminary third-quarter ZYNLONTA net product revenue of about $21.0 million and cash of $189.2 million, and the new share sales and warrant repricing add dilution for existing shareholders.
Private placement of 12,911,347 common shares at $1.42 per share, plus pre-funded warrants for 48,088,653 shares, expected to close October 22, 2026
Term loan prepayment of $70.0 million leaves $50.0 million outstanding; minimum liquidity covenant eliminated and a $65.0 million ZYNLONTA sales covenant set for the quarter ending December 31, 2026
HCR amendment removes the $150 million change-of-control payment and lets the company buy out royalties for $525 million by December 31, 2029 or $750 million from January 1, 2030
Preliminary Q3 2026 ZYNLONTA net product revenue of about $21.0 million; cash and equivalents of $189.2 million as of September 30, 2026
ADC Therapeutics reported second-quarter 2026 net product revenue of $18.6 million, up from $18.1 million a year earlier, and a net loss of $16.6 million, or $0.11 per share, down from $56.6 million, or $0.50 per share. The company also said the FDA raised substantial concerns about the benefit-risk of the LOTIS-5 trial after a pre-sBLA meeting, and it is assessing its regulatory path, which affects shareholders' view of the future approval path for ZYNLONTA.
Q2 2026 net product revenue was $18.6 million versus $18.1 million in Q2 2025; six-month revenue was $38.7 million versus $35.5 million.
Q2 2026 net loss was $16.6 million ($0.11 per share) versus $56.6 million ($0.50 per share) a year earlier; total operating expenses fell 29% to $44.7 million.
The FDA noted substantial concerns about the LOTIS-5 benefit-risk profile; the company plans to provide an update on regulatory strategy and timing in the near future.
Cash and cash equivalents were $219.1 million at June 30, 2026, down from $261.3 million at December 31, 2025; the company expects a cash runway at least into 2028.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ADC Therapeutics SA filing is on SEC EDGAR ↗. 8-K briefs of other companies →